;PMID: 2311333
;source_file_951.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..43] = [t:0..43]
;1)sentence:[e:49..163] = [t:49..163]
;2)section:[e:167..209] = [t:167..209]
;3)section:[e:213..291] = [t:213..291]
;4)sentence:[e:295..621] = [t:295..621]
;5)sentence:[e:622..981] = [t:622..981]
;6)sentence:[e:982..1253] = [t:982..1253]
;7)sentence:[e:1254..1547] = [t:1254..1547]
;8)sentence:[e:1548..1862] = [t:1548..1862]
;9)sentence:[e:1863..2016] = [t:1863..2016]
;10)section:[e:2020..2064] = [t:2020..2064]

;section 0 Span:0..43
;Clin Pharmacol Ther. 1990 Mar;47(3):313-22.
(SEC
  (FRAG (NNP:[0..4] Clin) (NNP:[5..14] Pharmacol) (NNP:[15..19] Ther)
        (.:[19..20] .) (CD:[21..25] 1990) (CC:[26..33] Mar;47-LRB-)
        (CD:[33..34] 3) (-RRB-:[34..35] -RRB-) (CD:[35..39] :313)
        (HYPH:[39..40] -) (CD:[40..42] 22) (.:[42..43] .)))

;sentence 1 Span:49..163
;Polymorphism in hydroxylation of mephenytoin and hexobarbital stereoisomers
;in  relation to hepatic P-450 human-2.
;[82..93]:substance:"mephenytoin"
;[98..124]:substance:"hexobarbital stereoisomers"
;[149..162]:cyp450:"P-450 human-2"
(SENT
  (NP-HLN
    (NP (NN:[49..61] Polymorphism))
    (PP (IN:[62..64] in)
      (NP
        (NP (NN:[65..78] hydroxylation))
        (PP (IN:[79..81] of)
          (NP
            (NP (NN:[82..93] mephenytoin)
              (NML-1 (-NONE-:[93..93] *P*)))
            (CC:[94..97] and)
            (NP (NN:[98..110] hexobarbital)
              (NML-1 (NNS:[111..124] stereoisomers)))))))
    (PP (IN:[125..127] in)
      (NP
        (NP (NN:[129..137] relation))
        (PP (TO:[138..140] to)
          (NP (JJ:[141..148] hepatic)
             (NN:[149..154] P-450) (NN:[155..162] human-2)))))
    (.:[162..163] .)))

;section 2 Span:167..209
;Yasumori T, Murayama N, Yamazoe Y, Kato R.
(SEC
  (FRAG (NNP:[167..175] Yasumori) (NNP:[176..177] T) (,:[177..178] ,)
        (NNP:[179..187] Murayama) (NNP:[188..189] N) (,:[189..190] ,)
        (NNP:[191..198] Yamazoe) (NNP:[199..200] Y) (,:[200..201] ,)
        (NNP:[202..206] Kato) (NNP:[207..209] R.)))

;section 3 Span:213..291
;Department of Pharmacology, School of Medicine, Keio University, Tokyo,
;Japan.
(SEC
  (FRAG (NNP:[213..223] Department) (IN:[224..226] of)
        (NNP:[227..239] Pharmacology) (,:[239..240] ,) (NNP:[241..247] School)
        (IN:[248..250] of) (NNP:[251..259] Medicine) (,:[259..260] ,)
        (NNP:[261..265] Keio) (NNP:[266..276] University) (,:[276..277] ,)
        (NNP:[278..283] Tokyo) (,:[283..284] ,) (NNP:[285..290] Japan)
        (.:[290..291] .)))

;sentence 4 Span:295..621
;Stereoselective 4'-hydroxylations of R-(-)-mephenytoin and S-(+)-mephenytoin
;and  3'-hydroxylation of R-(-)-hexobarbital and S-(+)-hexobarbital were
;determined in  liver microsomes of 14 Japanese subjects who were extensive
;metabolizers of  mephenytoin and in five Japanese subjects who were poor
;metabolizers of  mephenytoin.
;[332..349]:substance:"R-(-)-mephenytoin"
;[354..371]:substance:"S-(+)-mephenytoin"
;[397..415]:substance:"R-(-)-hexobarbital"
;[420..438]:substance:"S-(+)-hexobarbital"
;[536..547]:substance:"mephenytoin"
;[609..620]:substance:"mephenytoin"
(SENT
  (S
    (NP-SBJ-3
      (NP
        (NP (JJ:[295..310] Stereoselective) (NNS:[311..328] 4'-hydroxylations))
        (PP (IN:[329..331] of)
          (NP
            (NP (NN:[332..349] R--LRB---RRB--mephenytoin))
            (CC:[350..353] and)
            (NP (NN:[354..371] S--LRB-+-RRB--mephenytoin)))))
      (CC:[372..375] and)
      (NP
        (NP (NN:[377..393] 3'-hydroxylation))
        (PP (IN:[394..396] of)
          (NP
            (NP (NN:[397..415] R--LRB---RRB--hexobarbital))
            (CC:[416..419] and)
            (NP (NN:[420..438] S--LRB-+-RRB--hexobarbital))))))
    (VP (VBD:[439..443] were)
      (VP (VBN:[444..454] determined)
        (NP-3 (-NONE-:[454..454] *))
        (PP-LOC
          (PP (IN:[455..457] in)
            (NP
              (NP (NN:[459..464] liver) (NNS:[465..475] microsomes))
              (PP (IN:[476..478] of)
                (NP
                  (NP (CD:[479..481] 14) (JJ:[482..490] Japanese)
                      (NNS:[491..499] subjects))
                  (SBAR
                    (WHNP-2 (WP:[500..503] who))
                    (S
                      (NP-SBJ-2 (-NONE-:[503..503] *T*))
                      (VP (VBD:[504..508] were)
                        (NP-PRD
                          (NP (JJ:[509..518] extensive)
                              (NNS:[519..531] metabolizers))
                          (PP (IN:[532..534] of)
                            (NP (NN:[536..547] mephenytoin)))))))))))
          (CC:[548..551] and)
          (PP (IN:[552..554] in)
            (NP
              (NP (CD:[555..559] five) (JJ:[560..568] Japanese)
                  (NNS:[569..577] subjects))
              (SBAR
                (WHNP-1 (WP:[578..581] who))
                (S
                  (NP-SBJ-1 (-NONE-:[581..581] *T*))
                  (VP (VBD:[582..586] were)
                    (NP-PRD
                      (NP (JJ:[587..591] poor) (NNS:[592..604] metabolizers))
                      (PP (IN:[605..607] of)
                        (NP (NN:[609..620] mephenytoin))))))))))))
    (.:[620..621] .)))

;sentence 5 Span:622..981
;Content of P-450 human-2 assessed by Western blots was correlated  to
;microsomal S-(+)-mephenytoin 4'-hydroxylation, R-(-)-hexobarbital 3' 
;alpha-hydroxylation, and S-(+)-hexobarbital 3' beta-hydroxylation, and was
;less  correlated to R-(-)mephenytoin 4'-hydroxylation, R-(-)-hexobarbital 3' 
;beta-hydroxylation, and S-(+)-hexobarbital 3' alpha-hydroxylation.
;[633..646]:cyp450:"P-450 human-2"
;[703..720]:substance:"S-(+)-mephenytoin"
;[739..757]:substance:"R-(-)-hexobarbital"
;[787..805]:substance:"S-(+)-hexobarbital"
;[857..873]:substance:"R-(-)mephenytoin"
;[892..910]:substance:"R-(-)-hexobarbital"
;[939..957]:substance:"S-(+)-hexobarbital"
(SENT
  (S
    (NP-SBJ-1
      (NP
        (NP (NN:[622..629] Content))
        (PP (IN:[630..632] of)
          (NP (NN:[633..638] P-450) (NN:[639..646] human-2))))
      (VP (VBN:[647..655] assessed)
        (NP (-NONE-:[655..655] *))
        (PP-MNR (IN:[656..658] by)
          (NP (JJ:[659..666] Western) (NNS:[667..672] blots)))))
    (VP
      (VP (VBD:[673..676] was)
        (VP (VBN:[677..687] correlated)
          (NP-1 (-NONE-:[687..687] *))
          (PP-CLR (TO:[689..691] to)
            (NP
              (NP
                (ADJP-2 (JJ:[692..702] microsomal))
                (NN:[703..720] S--LRB-+-RRB--mephenytoin)
                 (NN:[721..737] 4'-hydroxylation))
              (,:[737..738] ,)
              (NP
                (ADJP-2 (-NONE-:[738..738] *P*))
                (NN:[739..757] R--LRB---RRB--hexobarbital) (CD:[758..759] 3)
                 (SYM:[759..760] ') (NN:[762..781] alpha-hydroxylation))
              (,:[781..782] ,) (CC:[783..786] and)
              (NP
                (ADJP-2 (-NONE-:[786..786] *P*))
                (NN:[787..805] S--LRB-+-RRB--hexobarbital) (CD:[806..807] 3)
                 (SYM:[807..808] ') (NN:[809..827] beta-hydroxylation))))))
      (,:[827..828] ,) (CC:[829..832] and)
      (VP (VBD:[833..836] was)
        (ADVP (RBR:[837..841] less))
        (VP (VBN:[843..853] correlated)
          (NP-1 (-NONE-:[853..853] *))
          (PP-CLR (TO:[854..856] to)
            (NP
              (NP (NN:[857..873] R--LRB---RRB-mephenytoin)
                  (NN:[874..890] 4'-hydroxylation))
              (,:[890..891] ,)
              (NP (NN:[892..910] R--LRB---RRB--hexobarbital) (CD:[911..912] 3)
                  (SYM:[912..913] ') (NN:[915..933] beta-hydroxylation))
              (,:[933..934] ,) (CC:[935..938] and)
              (NP (NN:[939..957] S--LRB-+-RRB--hexobarbital) (CD:[958..959] 3)
                  (SYM:[959..960] ') (NN:[961..980] alpha-hydroxylation)))))))
    (.:[980..981] .)))

;sentence 6 Span:982..1253
;Antibodies  raised against P-450 human-2 inhibited microsomal
;S-(+)-mephenytoin  4'-hydroxylation efficiently but was less efficient on
;R-(-)-mephenytoin  4'-hydroxylation in extensive metabolizers and on
;4'-hydroxylation of  mephenytoin enantiomers in poor metabolizers.
;[982..992]:substance:"Antibodies"
;[1009..1022]:cyp450:"P-450 human-2"
;[1044..1061]:substance:"S-(+)-mephenytoin"
;[1118..1135]:substance:"R-(-)-mephenytoin"
;[1208..1231]:substance:"mephenytoin enantiomers"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[982..992] Antibodies))
      (VP (VBN:[994..1000] raised)
        (NP (-NONE-:[1000..1000] *))
        (PP (IN:[1001..1008] against)
          (NP (NN:[1009..1014] P-450) (NN:[1015..1022] human-2)))))
    (VP
      (VP (VBD:[1023..1032] inhibited)
        (NP (JJ:[1033..1043] microsomal)
            (NN:[1044..1061] S--LRB-+-RRB--mephenytoin)
            (NN:[1063..1079] 4'-hydroxylation))
        (ADVP (RB:[1080..1091] efficiently)))
      (CC:[1092..1095] but)
      (VP
        (VP (VBD:[1096..1099] was)
          (ADJP-PRD (RBR:[1100..1104] less) (JJ:[1105..1114] efficient))
          (PP=1 (IN:[1115..1117] on)
            (NP (NN:[1118..1135] R--LRB---RRB--mephenytoin)
                (NN:[1137..1153] 4'-hydroxylation)))
          (PP-LOC=2 (IN:[1154..1156] in)
            (NP (JJ:[1157..1166] extensive) (NNS:[1167..1179] metabolizers))))
        (CC:[1180..1183] and)
        (VP
          (PP=1 (IN:[1184..1186] on)
            (NP
              (NP (NN:[1187..1203] 4'-hydroxylation))
              (PP (IN:[1204..1206] of)
                (NP (NN:[1208..1219] mephenytoin) (NNS:[1220..1231] enantiomers)))))
          (PP-LOC=2 (IN:[1232..1234] in)
            (NP (JJ:[1235..1239] poor) (NNS:[1240..1252] metabolizers))))))
    (.:[1252..1253] .)))

;sentence 7 Span:1254..1547
;The antibodies also inhibited  R-(-)-hexobarbital 3' alpha-hydroxylation and
;S-(+)-hexobarbital 3'  beta-hydroxylation but did not effectively inhibit the
;hydroxylation of the two  other optical isomers of hexobarbital in extensive
;metabolizers and of four  stereoisomers in poor metabolizers.
;[1258..1268]:substance:"antibodies"
;[1285..1303]:substance:"R-(-)-hexobarbital"
;[1331..1349]:substance:"S-(+)-hexobarbital"
;[1449..1456]:substance:"isomers"
;[1460..1472]:substance:"hexobarbital"
;[1512..1525]:substance:"stereoisomers"
(SENT
  (S
    (NP-SBJ (DT:[1254..1257] The) (NNS:[1258..1268] antibodies))
    (VP
      (VP
        (ADVP (RB:[1269..1273] also))
        (VBD:[1274..1283] inhibited)
        (NP
          (NP (NN:[1285..1303] R--LRB---RRB--hexobarbital) (CD:[1304..1305] 3)
              (SYM:[1305..1306] ') (NN:[1307..1326] alpha-hydroxylation))
          (CC:[1327..1330] and)
          (NP (NN:[1331..1349] S--LRB-+-RRB--hexobarbital) (CD:[1350..1351] 3)
              (SYM:[1351..1352] ') (NN:[1354..1372] beta-hydroxylation))))
      (CC:[1373..1376] but)
      (VP (VBD:[1377..1380] did) (RB:[1381..1384] not)
        (ADVP (RB:[1385..1396] effectively))
        (VP
          (VP (VB:[1397..1404] inhibit)
            (NP
              (NP (DT:[1405..1408] the) (NN:[1409..1422] hydroxylation))
              (PP=2 (IN:[1423..1425] of)
                (NP
                  (NP (DT:[1426..1429] the) (CD:[1430..1433] two)
                      (JJ:[1435..1440] other) (JJ:[1441..1448] optical)
                      (NNS:[1449..1456] isomers))
                  (PP (IN:[1457..1459] of)
                    (NP (NN:[1460..1472] hexobarbital))))))
            (PP-LOC=3 (IN:[1473..1475] in)
              (NP (JJ:[1476..1485] extensive) (NNS:[1486..1498] metabolizers))))
          (CC:[1499..1502] and)
          (VP
            (PP=2 (IN:[1503..1505] of)
              (NP (CD:[1506..1510] four) (NNS:[1512..1525] stereoisomers)))
            (PP-LOC=3 (IN:[1526..1528] in)
              (NP (JJ:[1529..1533] poor) (NNS:[1534..1546] metabolizers)))))))
    (.:[1546..1547] .)))

;sentence 8 Span:1548..1862
;These findings indicate the close  relationship between polymorphic
;mephenytoin 4'-hydroxylation and two  stereospecific hexobarbital
;hydroxylations, and they suggest that P-450 human-2  is a typical
;S-(+)-mephenytoin 4'-hydroxylase and a major hexobarbital  3'-hydroxylase in
;the livers of extensive metabolizers.
;[1616..1627]:substance:"mephenytoin"
;[1669..1681]:substance:"hexobarbital"
;[1720..1733]:cyp450:"P-450 human-2"
;[1748..1780]:substance:"S-(+)-mephenytoin 4'-hydroxylase"
;[1793..1821]:substance:"hexobarbital  3'-hydroxylase"
(SENT
  (S
    (S
      (NP-SBJ (DT:[1548..1553] These) (NNS:[1554..1562] findings))
      (VP (VBP:[1563..1571] indicate)
        (NP
          (NP (DT:[1572..1575] the) (JJ:[1576..1581] close)
              (NN:[1583..1595] relationship))
          (PP (IN:[1596..1603] between)
            (NP
              (NP (JJ:[1604..1615] polymorphic) (NN:[1616..1627] mephenytoin)
                  (NN:[1628..1644] 4'-hydroxylation))
              (CC:[1645..1648] and)
              (NP (CD:[1649..1652] two) (JJ:[1654..1668] stereospecific)
                  (NN:[1669..1681] hexobarbital)
                  (NNS:[1682..1696] hydroxylations)))))))
    (,:[1696..1697] ,) (CC:[1698..1701] and)
    (S
      (NP-SBJ (PRP:[1702..1706] they))
      (VP (VBP:[1707..1714] suggest)
        (SBAR (IN:[1715..1719] that)
          (S
            (NP-SBJ (NN:[1720..1725] P-450) (NN:[1726..1733] human-2))
            (VP (VBZ:[1735..1737] is)
              (NP-PRD
                (NP (DT:[1738..1739] a) (JJ:[1740..1747] typical)
                   (NN:[1748..1765] S--LRB-+-RRB--mephenytoin)
                   (NN:[1766..1780] 4'-hydroxylase))
                (CC:[1781..1784] and)
                (NP (DT:[1785..1786] a) (JJ:[1787..1792] major)
                   (NN:[1793..1805] hexobarbital)
                   (NN:[1807..1821] 3'-hydroxylase)))
              (PP-LOC (IN:[1822..1824] in)
                (NP
                  (NP (DT:[1825..1828] the) (NNS:[1829..1835] livers))
                  (PP (IN:[1836..1838] of)
                    (NP (JJ:[1839..1848] extensive)
                        (NNS:[1849..1861] metabolizers))))))))))
    (.:[1861..1862] .)))

;sentence 9 Span:1863..2016
;The findings were  further supported by the experiments that used P-450
;human-2 complementary  dexoyribonucleic acid-derived protein in yeast
;microsomes.
;[1929..1942]:cyp450:"P-450 human-2"
;[1958..1995]:substance:"dexoyribonucleic acid-derived protein"
(SENT
  (S
    (NP-SBJ-2 (DT:[1863..1866] The) (NNS:[1867..1875] findings))
    (VP (VBD:[1876..1880] were)
      (ADVP (RB:[1882..1889] further))
      (VP (VBN:[1890..1899] supported)
        (NP-2 (-NONE-:[1899..1899] *))
        (PP (IN:[1900..1902] by)
          (NP-LGS
            (NP (DT:[1903..1906] the) (NNS:[1907..1918] experiments))
            (SBAR
              (WHNP-1 (WDT:[1919..1923] that))
              (S
                (NP-SBJ-1 (-NONE-:[1923..1923] *T*))
                (VP (VBD:[1924..1928] used)
                  (NP
                     (NN:[1929..1934] P-450) (NN:[1935..1942] human-2)
                    (JJ:[1943..1956] complementary)
                    
                    (ADJP
                      (NML (JJ:[1958..1974] dexoyribonucleic)
                           (NN:[1975..1979] acid))
                      (HYPH:[1979..1980] -) (VBN:[1980..1987] derived))
                    (NN:[1988..1995] protein))
                  (PP (IN:[1996..1998] in)
                    (NP (NN:[1999..2004] yeast) (NNS:[2005..2015] microsomes))))))))))
    (.:[2015..2016] .)))

;section 10 Span:2020..2064
;PMID: 2311333 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[2020..2024] PMID) (::[2024..2025] :) (CD:[2026..2033] 2311333)
        (IN:[2034..2035] -LSB-) (NNP:[2035..2041] PubMed) (HYPH:[2042..2043] -)
        (JJ:[2044..2051] indexed) (IN:[2052..2055] for)
        (NNP:[2056..2064] MEDLINE-RSB-)))
